Nanomedicines consisting of nanoparticles for targeted drug delivery to specific tissues and cells offer new solutions for cancer diagnosis and therapy. Understanding the interdependency of physiochemical properties of nanomedicines, in correlation to their biological responses and functions, is crucial for their further development of as cancer-fighters.
Like discriminating thieves, prostate cancer tumors scavenge and hoard copper that is an essential element in the body. But such avarice may be a fatal weakness. Researchers at Duke Medicine have found a way to kill prostate cancer cells by delivering a trove of copper along with a drug that selectively destroys the diseased cells brimming with the mineral, leaving non-cancer cells healthy.
Researchers at The Scripps Research Institute have created a synthetic molecule that mimics “good” cholesterol and have shown it can reduce plaque buildup in the arteries of animal models. The molecule, taken orally, improved cholesterol in just two weeks.
The Centers for Disease Control and Prevention has said that at least 2 million Americans are sickened by antibiotic resistant infections each year and survive. Twenty-three thousand die. These experiences leave deep impressions not just on the patients but on their family and friends.
Biomedical engineering researchers have developed a drug delivery system consisting of nanoscale “cocoons” made of DNA that target cancer cells and trick the cells into absorbing the cocoon before unleashing anticancer drugs. The new system is DNA-based, which means it is biocompatible and less toxic to patients than systems that use synthetic materials.
Hepatitis C, an infectious disease of the liver caused by the hepatitis C virus (HCV), affects 160 million people worldwide. There’s no vaccine for HCV and the few treatments that are available do not work on all variants of the virus. Before scientists can develop potential vaccines and additional therapies they must first thoroughly understand the molecular-level activity that takes place when the virus infects a host cell.
Tuberculosis is caused by a bacterium that infects the lungs of an estimated 8.6 million people worldwide. The fight against the disease is hampered by the fact that treatment requires a long time and that the bacterium often develops multi-drug resistance. Scientists have used a sensitive screening assay to test new compounds that can be used against the bacterium, and have discovered two small molecules that show remarkable promise.
A study suggests that do-it-yourself flu vaccine might be possible. Researchers found that military folks who squirted a nasal vaccine up their noses were as well-protected as others who got it from health workers. The study leader says there is no reason that ordinary people could not be taught to give the vaccine, especially for children who might be less scared if they received it from mom or dad.
Green tea has long been known for its anti-oxidant, anti-cancer, anti-aging and anti-microbial properties. A group of researchers from the Institute of Bioengineering and Nanotechnology in Singapore has taken the health benefits of green tea to the next level by using one of its ingredients, the antioxidant epigallocatechin gallate, to develop a drug delivery system that kills cancer cells more efficiently.
Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical candidates haven’t worked that well. Now, scientists have developed a new way to deliver vaccines that successfully stifled tumor growth when tested in laboratory mice. And the key is in the vaccine’s unique stealthy nanoparticles.
The discovery of a gene mutation that causes a rare premature aging disease could lead to the development of drugs that block the rapid, unstoppable cell division that makes cancer so deadly. Scientists at the Univ. of Michigan recently discovered a protein mutation that causes the devastating disease dyskeratosis congenita, in which precious hematopoietic stem cells can't regenerate and make new blood.
Given a choice, most patients would prefer to take a drug orally instead of getting an injection. Unfortunately, many drugs, can’t be given as a pill because they get broken down in the stomach before they can be absorbed. To help overcome that obstacle, researchers have devised a novel drug capsule coated with tiny needles that can inject drugs directly into the lining of the stomach after swallowed.
Over the past few years, a class of compounds called ADEPs (cyclic acyldepsipeptides) has emerged as a promising new weapon in the fight against drug-resistant bacteria. The compounds work by attaching themselves to a cellular enzyme called ClpP, which bacterial cells use to rid themselves of harmful proteins. With an ADEP attached, ClpP can’t function properly, and the bacterial cell dies.
Massachusetts Institute of Technology engineers have devised a way to rapidly test hundreds of different drug-delivery vehicles in living animals, making it easier to discover promising new ways to deliver a class of drugs called biologics, which includes antibodies, peptides, RNA and DNA, to human patients.
The 2nd Annual Pharma Data Analytics Conference will enable senior-level analytics professionals to improve the bottom line of their business through utilizing the potential of big data. Driven by single-track case study presentations from Pfizer, Celgene, Novartis, Merck and many others, this program will explore recent trends in the pharmaceutical environment, including the influence of analytics in the commercial space, data visualization tools and techniques and methodologies for forecasting across multiple business units.
An Oak Ridge National Laboratory team has unlocked the enzymatic synthesis process of rare sugars, which are useful in developing drugs with low side effects. In a recently published paper, the team reported the pioneering use of neutron and x-ray crystallography and HPC to study how the enzyme D-xylose isomerase, or XI, can cause a biochemical reaction in natural sugar to produce rare sugars.
Bacillus anthracis bacteria have very efficient machinery for injecting toxic proteins into cells, leading to the potentially deadly infection known as anthrax. A team of Massachusetts Institute of Technology (MIT) researchers has now hijacked that delivery system for a different purpose: administering cancer drugs.
For decades, researchers have tried to develop broadly effective vaccines to prevent the spread of illnesses such as HIV, malaria and tuberculosis. While limited progress has been made along these lines, there are still no licensed vaccinations available that can protect most people from these devastating diseases. So what are immunologists to do when vaccines just aren't working?
Scientists at The Scripps Research Institute have devised a new antibiotic based on vancomycin that is powerfully effective against vancomycin-resistant strains of MRSA and other disease-causing bacteria. The new vancomycin analog appears to have not one but two distinct mechanisms of anti-microbial action, against which bacteria probably cannot evolve resistance quickly.
Malaria threatens more than 40% of the world’s population and kills up to 1.2 million people worldwide each year. Many of these deaths happen in Sub-Saharan Africa in children under the age of five and pregnant woman. The estimates for clinical infection is somewhere between 300 to 500 million people each year, worldwide.
Gilead Sciences has reached a deal with several generic drugmakers to produce a cheaper version of its popular, $1,000-per-pill hepatitis C drug Sovaldi for use in developing countries. Gilead said that the India-based companies will make a generic version of Sovaldi, also known as sofosbuvir, and another investigational drug for distribution in 91 countries.
Doctors in many U.S. hospitals are unnecessarily prescribing multiple antibiotics for several days when just one would do the job, a new study suggests. Health officials have sounded alarms that overuse of antibiotics is helping to breed dangerous bacteria that are increasingly resistant to treatment. Much of the attention has been on doctor offices that wrongly prescribe bacteria-targeting antibiotics for illnesses caused by viruses.
U.S. regulators have approved the first drug in a new class of cancer medicines that work by stimulating the immune system, a Merck drug developed for treating deadly skin cancer. The Food and Drug Administration says it has granted accelerated approval to Merck's Keytruda, for treating melanoma that's spread or can't be surgically removed, in patients previously treated with another drug.
Eli Lilly and Co. plans to seek approval early next year for a new insulin it developed after the diabetes treatment fared better than the competition in two late-stage clinical studies. The Indianapolis drugmaker said Thursday peglispro produced statistically significant lower blood sugar levels in patients when compared to people who took the Sanofi insulin Lantus in two late-stage studies of people with type 1 diabetes.
A self-assembling nanoparticle designed by a Univ. of Connecticut (UConn) professor is the key component of a potent new malaria vaccine that is showing promise in early tests. For years, scientists trying to develop a malaria vaccine have been stymied by the malaria parasite’s ability to transform itself and “hide” in the liver and red blood cells of an infected person to avoid detection by the immune system.